66679-56-9Relevant academic research and scientific papers
A journey from benzanilides to dithiobenzanilides: Synthesis of selective spasmolytic compounds
Brunhofer, Gerda,Granig, Walter H.,Studenik, Christian R.,Erker, Thomas
experimental part, p. 994 - 1001 (2011/03/18)
A series of dithiobenzanilide derivatives was synthesized and each compound was evaluated for its ability to reduce KCl-induced contractions of smooth muscle preparations of the guinea pig. Starting from a recent publication describing benzanilide derivatives as antispasmodic agents, structure-activity guided synthesis was performed to obtain compounds with improved spasmolytic activity. First, compounds with two amide bonds were designed and second, both amide oxygens were replaced by two sp2 sulfur atoms resulting in dithiobenzanilide derivatives. The most potent antispasmodic dithiobenzanilide 19 showed improved activity with an IC50 value of 0.4 μM. Moreover, the study also demonstrated that these active compounds were able to antagonize the effect of spasmogens like acetylcholine and phenylephrine and that the activity is not mediated by activation of ATP-dependent potassium channels (KATP-channels) or inhibition of endothelial nitric oxide synthase (eNOS).
Synthesis and biological activity of novel 1,2-disubstituted benzene derivatives as factor Xa inhibitors
Koshio, Hiroyuki,Hirayama, Fukushi,Ishihara, Tsukasa,Shiraki, Ryouta,Shigenaga, Takeshi,Taniuchi, Yuta,Sato, Kazuo,Moritani, Yumiko,Iwatsuki, Yoshiyuki,Kaku, Seiji,Katayama, Naoko,Kawasaki, Tomihisa,Matsumoto, Yuzo,Sakamoto, Shuichi,Tsukamoto, Shin-Ichi
, p. 1305 - 1323 (2007/10/03)
Factor Xa (fXa) is a serine protease that plays a pivotal role in the coagulation cascade. High-throughput screening of the Yamanouchi compound library yielded lead compound 1 with the ability to inhibit fXa at micromolar concentrations. To improve its fX
Antithrombotic agents
-
, (2008/06/13)
This application relates to a compound of formula (I), a pharmaceutically acceptable salt of the compound, or a prodrug thereof, as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.
1,2-Dibenzamidobenzene inhibitors of human factor Xa
Herron, David K.,Goodson Jr., Theodore,Wiley, Michael R.,Weir, Leonard C.,Kyle, Jeffrey A.,Yee, Ying K.,Tebbe, Ann Louise,Tinsley, Jennifer M.,Mendel, David,Masters, John J.,Franciskovich, Jeffry B.,Sawyer, J. Scott,Beight, Douglas W.,Ratz, Andrew M.,Milot, Guy,Hall, Steven E.,Klimkowski, Valentine J.,Wikel, James H.,Eastwood, Brian J.,Towner, Richard D.,Gifford-Moore, Donetta S.,Craft, Trelia J.,Smith, Gerald F.
, p. 859 - 872 (2007/10/03)
High-throughput screening of a combinatorial library of diamidophenols yielded lead compounds with the ability to inhibit human factor Xa (fXa) at micromolar concentrations (e.g. compound 4, fXa apparent K(ass) = 0.64 x 106 L/mol). SAR studies in this novel structural series of fXa inhibitors showed that the phenolic hydroxyl group was not essential for activity. The best activity was found in substituted 1,2-dibenzamidobenzenes in which the phenyl group of one benzoyl group (A-ring) was substituted in the 4-position with relatively small lipophilic or polarizable groups such as methoxy, vinyl, or chloro and the phenyl group of the other benzoyl group (B-ring) was substituted in the 4-position with larger lipophilic groups such as tertbutyl or dimethylamino. The central phenyl ring (C-ring) tolerated a wide variety of substituents, but methoxy, methanesulfonamido, hydroxyl, and carboxyl substitution produced slightly higher levels of activity than other substituents when present in combination with favorable B-ring substitution. Methylation of the amide nitrogen atoms was found to greatly decrease activity. Compound 12 is the highest affinity fXa inhibitor in this group of compounds, having fXa apparent K(ass) = 25.5 x 106 L/mol, about 40x more active than the original lead. This lead series does not show potent inhibition of human thrombin. A model for the binding of these ligands to the fXa active site is proposed. The model is consistent with the observed SAR and can serve to guide future SAR studies.
